Tag: Everest Medicines Limited

Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately...

Everest Medicines (HKG 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...

- Officially Benefiting Mainland China Patients Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization...

- by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Everest Medicines (HKEX 1952.HK, Everest, or the...

Officially Beginning to Benefit Asian Patients Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10...

Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...